133 related articles for article (PubMed ID: 9237175)
1. Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma.
Silva EG; Tornos CS; Malpica A; Gershenson DM
Mod Pathol; 1997 Jul; 10(7):663-7. PubMed ID: 9237175
[TBL] [Abstract][Full Text] [Related]
2. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
4. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma.
Killackey MA; Davis AR
Gynecol Oncol; 1993 Nov; 51(2):171-4. PubMed ID: 8276289
[TBL] [Abstract][Full Text] [Related]
5. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
7. Correspondence re: Silva G, Torno, C, Malpica A, Gershenson, DM. Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma. Mod Pathol 1997;10:663-7.
Mensch AH
Mod Pathol; 1997 Nov; 10(11):1172. PubMed ID: 9388071
[No Abstract] [Full Text] [Related]
8. Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma.
Mills SE; Andersen WA; Fechner RE; Austin MB
Am J Surg Pathol; 1988 Nov; 12(11):827-34. PubMed ID: 3189692
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
10. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
11. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
12. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
Gershenson DM; Sun CC; Lu KH; Coleman RL; Sood AK; Malpica A; Deavers MT; Silva EG; Bodurka DC
Obstet Gynecol; 2006 Aug; 108(2):361-8. PubMed ID: 16880307
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
Vereczkey I; Tóth E; Orosz Z
Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
[TBL] [Abstract][Full Text] [Related]
14. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
16. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma.
Bancher-Todesca D; Neunteufel W; Williams KE; Prainsack D; Breitenecker G; Friedlander ML; Hacker NF
Gynecol Oncol; 1998 Dec; 71(3):344-7. PubMed ID: 9887228
[TBL] [Abstract][Full Text] [Related]
17. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors).
Seidman JD; Kurman RJ
Cancer; 2002 Aug; 95(4):675-6. PubMed ID: 12209708
[No Abstract] [Full Text] [Related]
18. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
19. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
20. Epithelial ovarian tumors of low malignant potential.
Massad LS; Hunter VJ; Szpak CA; Clarke-Pearson DL; Creasman WT
Obstet Gynecol; 1991 Dec; 78(6):1027-32. PubMed ID: 1945202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]